The Use of Antibodies in Small-Molecule Drug Discovery

Abstract

Antibodies are powerful research tools that can be used in many areas of biology to probe, measure, and perturb various biological structures. Successful drug discovery is dependent on the correct identification of a target implicated in disease, coupled with the successful selection, optimization, and development of a candidate drug. Because of their specific binding characteristics, with regard to specificity, affinity, and avidity, coupled with their amenability to protein engineering, antibodies have become a key tool in drug discovery, enabling the quantification, localization, and modulation of proteins of interest. This review summarizes the application of antibodies and other protein affinity reagents as specific research tools within the drug discovery process.

Claudin-2 Expression Levels in Ulcerative Colitis: Development and Validation of an In-Situ Hybridisation Assay for Therapeutic Studies

“…In agreement with a number of papers published, an antibody validation strategy was formulated to determine the selectivity, specificity and IHC compatibility of the selected antibodies [22],[23], [24]].…”

EMMPRIN-Targeted Magnetic Nanoparticles for In Vivo Visualization and Regression of Acute Myocardial Infarction

“…The use of antibody-mediated targeting of proteins has been successfully evaluated in animal models of disease 32 . However, such an immunological approach was only effective in very few studies in humans, and therefore the translation to the clinic is limited for reasons that include immune cross reactivity, antibody-mediated side effects, or lack of desired therapeutic improvement.…”

AI Case Studies: Potential for Human Health, Space Exploration and Colonisation and a Proposed Superimposition of the Kubler-Ross Change Curve on the Hype Cycle

“…Reasons underlying factorial and comprise contributions from basic non translational science, clinical efficacy and safety, regulatory and commercial issues, together with the need to tackle increasingly challenging areas of human disease where the pathophysiology is often heterogeneous. Significant advances in screening [31], use of antibodies [32], [33] and generation of new modalities for targets previously thought as intractable [34], [35], phenome technologies applied to large samples sets and small volume sample size [36] mean that it is now possible to generate very large data sets designed to assist the selection of candidate drugs and their progression through lengthy and costly clinical trials. One critical part of the drug discovery process which underpins all downstream further drug development in both non-clinical and clinical phases based manual handling of potential new medical entities and to match appropriately designed drugs to the genotype and phenotype of the patient.…”